[Federal Register Volume 66, Number 106 (Friday, June 1, 2001)]
[Notices]
[Pages 29816-29821]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-13738]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 01102]


Cancer Surveillance Research With Data Enhancement and 
Utilization, Notice of Availability of Funds

A. Purpose

    The Centers for Disease Control and Prevention (CDC) announce the 
availability of fiscal year (FY) 2001 funds for a cooperative agreement 
program to support priority cancer surveillance research with data 
enhancement and utilization activities. This program addresses the 
``Healthy People 2010'' priority areas related to Cancer.
    The purpose of this program is to utilize data from the National 
Program of Cancer Registries (NPCR) to perform enhanced surveillance 
and operational research to include developing, conducting and 
evaluating cancer surveillance research projects targeting breast, 
colorectal, prostate, ovarian, and oral/pharyngeal cancers.
    Applicants with interest in innovative cancer surveillance research 
activities are encouraged to apply under this announcement and, if 
appropriate, to partner with universities.
    This program consists of 4 parts:

Part I--Breast/Colorectal/Prostate (BCP) Cancer Patterns of Care (POC), 
Recurrence, and Survival (Optional Breast Cancer Screening Linkage 
Component)

    The purpose of Part I is to conduct cancer surveillance research by 
comparing detailed clinical information including stage, diagnostic 
investigations used to assess stage (determinants of stage), and 
treatment in large, random samples of patients with female breast, 
prostate and colorectal cancers.
    The purpose of the Optional Breast Cancer Screening Linkage 
Component is to validate and assess the completeness and accuracy of 
information contained in the state Breast and Cervical Cancer Early 
Detection Program (BCCEDP) minimum data elements (MDE's) and to

[[Page 29817]]

sample for comparison of treatment of early stage breast cancer.

Part II--Reporting Pathology Protocols (colon and rectum)

    The purpose of Part II is to implement The College of American 
Pathologists (CAP) Reporting Protocol for cancers of the colon and 
rectum.

Part III--Ovarian Cancer Patterns of Care

    The purpose of Part III is to evaluate specific information related 
to the diagnosis and treatment of ovarian cancer, including: physician 
specialty, accuracy of staging and treatment data, chemotherapy 
treatment data, survival rates, and recurrence.

Part IV--Oral/Pharyngeal Cancer: Data Completeness and Quality

    The purpose of Part IV is to evaluate the completeness, timeliness 
and quality of oral and pharyngeal cancer and to apply methods to 
improve data collection, reliability, and validity.

B. Eligible Applicants

    Part I--Eligibility is limited to those population-based cancer 
registries (hereafter referred to as NPCR registries) listed in 
Appendix B. Determination of eligibility is based upon silver or gold 
certification by the North American Association of Central Cancer 
Registries (NAACCR) (with the exception of the timeliness standard) for 
diagnosis year 1997. This diagnosis year certification is the most 
recent available from NAACCR.
    Part II--Eligible applicants are limited to NPCR registries which 
can demonstrate through a letter of support at least one effective 
partnership with a laboratory or laboratory vendor providing pathologic 
diagnostic services in a National Cancer Institute (NCI) designated 
comprehensive cancer or clinical cancer center facility in their state. 
Eligible states are listed in Appendix C.
    Part III--Eligibility for Part III is limited to NPCR registries 
listed in Appendix B. Determination of eligibility is based upon NAACCR 
silver or gold certification (with the exception of the timeliness 
standard) for diagnosis year 1997.
    Part IV--Eligibility for Part IV is limited to NPCR registries 
listed in Appendix B. Determination of eligibility is based upon NAACCR 
silver or gold certification (with the exception of the timeliness 
standard) for 1997. Multiple registries may submit a joint application.

C. Availability of Funds

    Approximately $3,151,000 is available in FY 2001 to fund the 
following categories.

Part I--BCP Cancer Patterns of Care, Recurrence, and Survival

    Approximately $2,056,000 is available in FY 2001 to fund 
approximately eight to ten awards. It is expected that the average 
award will be $293,000, ranging from $260,000 to $325,000.

Part II--Reporting Pathology Protocols

    Approximately $300,000 is available in FY 2001 to fund 
approximately two awards. It is expected that the average award will be 
$150,000, ranging from $125,000 to $175,000.

Part III--Ovarian Cancer Patterns of Care

    Approximately $670,000 is available in FY 2001 to fund 
approximately three awards. It is expected that the average award will 
be $235,000, ranging from $200,000 to $270,000.

Part IV--Oral/Pharyngeal Cancer: Data Completeness and Quality

    Approximately $125,000 is available in FY 2001 to fund up to two 
awards. It is expected that the average award will be $92,000, ranging 
from $60,000 to $125,000.
    Applicants may apply for one or more parts depending upon 
eligibility. It is expected that awards will begin on or about 
September 30, 2001, and will be made for a 12-month budget period 
within a project period of up to three years. Funding estimates may 
change.
    Continuation awards within an approved project period will be made 
on the basis of satisfactory progress as evidenced by required reports, 
research progress, and the availability of funds.

D. Program Requirements

    In conducting activities to achieve the purposes of Parts I-IV of 
this program, the recipient will be responsible for the activities 
under 1. (Recipient Activities), and CDC will be responsible for the 
activities listed under 2. (CDC Activities).
1. Recipient Activities
    Recipients for all parts will be responsible for the following 
activities:
    a. Collaborate with other successful recipients in part-specific 
activities.
    b. Participate in protocol development to include the design of the 
study, design of the instruments, development of methods and procedures 
for the study, collection of the data, analysis and interpretation of 
the data, and dissemination of results.
    c. Assist in the development of a research protocol for 
Institutional Review Board (IRB) review by all cooperating institutions 
participating in the research project. The CDC IRB will review and 
approve the protocol initially and on at least an annual basis until 
the research project is completed.
    d. Assure and maintain the confidentiality of all study data.
    e. Develop technical reports or manuscripts for peer-reviewed 
publications as appropriate.
    Specific activities for each part are as follows:

Part I

    a. Participate in a collaborative North American/European project 
between population-based cancer registries such as Phase 2 of the 
Concord Study found in Appendix G.
    b. Participate in additional studies of patterns of care for 
cancers of high public health importance in the U.S., including early 
stage female breast cancer, stage III colon cancer, and prostate 
cancer.
    c. Identify appropriate number of cases as specified in Appendix E.
    d. Provide study data to the Data Analysis Centre, located at the 
Istituto Superiore di Sanita in Rome, Italy, with no direct identifying 
information, such as name, address or any public identification code.
    e. Perform joint analysis with data from other registries and other 
countries.

Part I (Option)

    a. Conduct a probabilistic linkage between the state BCCEDP and the 
state cancer registry.
    b. Resolve potential matched records identified by the 
probabilistic linkage.
    C. Identify appropriate number of cases as specified in Appendix E.
    d. Collaborate with other successful recipients of the Part I 
option in the resolution of data quality issues and conduct special 
analyses relevant to the linkage of registry and BCCEDP files.

Part II

    a. Develop, in collaboration with other successful recipients, 
strategies to implement the CAP reporting protocols for cancers of the 
colon and rectum.
    b. Develop electronic reporting capacities to relate data from the 
protocols to an appropriate cancer registry.
    c. Implement CAP's reporting protocol for cancers of the colon and 
rectum.
    d. Participate with other successful applicants and other key 
groups to share expertise and experiences.

[[Page 29818]]

    e. Provide written feedback and recommendations regarding the 
protocols to improve the protocols for cancers of the colon and rectum 
that will meet the needs of pathologists and cancer registries.

Part III

    a. Identify a minimum of 1,500 ovarian cancer cases diagnosed 
between January 1, 1995, and December 31, 1999 within the state.
    b. Evaluate medical records to identify information related to the 
diagnosis and treatment of ovarian cancer, such as: physician 
specialty, accuracy of staging and treatment data, chemotherapy 
treatment data, survival rates, and recurrence. chemotherapeutic drugs 
provided to the patient.
    c. Conduct a linkage between the state cancer registry file and the 
state mortality file to identify deaths that have occurred among 
ovarian cancer patients diagnosed in 1995-1999.
    d. Evaluate differences between cancer stage and treatment data 
identified during this study and the stage of ovarian cancer and cancer 
treatment initially reported to the cancer registry.

Part IV

    a. Develop a protocol for auditing completeness and quality of oral 
cancer data, including at a minimum, an assessment of the quality of 
the following variables: stage at diagnosis, diagnosis year, diagnosis 
day, date of birth, race, site, subsite, histology, grade, sequence, 
laterality, gender, and treatment.
    b. Determine completeness, timeliness, and quality of the registry 
data on oral and pharyngeal cancers (defined by ICD-O-2 as C00-C14; 
ICD-9 as 140-149; or as defined by other codes) at several time 
intervals.
    c. Identify any unique problems associated with reporting and 
tabulating data on oral and pharyngeal cancers, including assessment of 
source data and reporting from non-hospital facilities, such as 
pathology laboratories, dental clinics, and oral surgeons.
    d. Estimate the number of oral and pharyngeal cases diagnosed and 
treated in non-hospital facilities.
    e. Evaluate any deficiencies in completeness, timeliness, and 
quality of oral/pharyngeal cancer data, and the potential effects of 
such deficiencies on the reliability and validity of incidence and 
survival estimates. Propose specific solutions to the deficiencies 
identified.
    f. Evaluate potential strategies for collapsing data in order to 
obtain reliable and stable estimates of incidence, e.g., by combining 
data for anatomical sites or across years.
    g. Identify the resources necessary to maintain completeness, 
timeliness, and quality of registry data on oral and pharyngeal cancer.
    h. Serve as the focal point for the development and dissemination 
of media releases, reports and publications.
2. CDC Activities
    CDC will be responsible for the following activities for all parts:
    a. Participate in a post-award meeting for information sharing, 
problem solving, and research protocol development.
    b. Provide ongoing consultation and technical assistance to 
successful recipients.
    c. Collaborate in the design of studies, to include development of 
sampling procedures, design of the instruments, development of methods 
and procedures for the studies, collection of data, analysis and 
interpretation of data, resolution of data quality issues and 
dissemination of results.
    d. Assist in the development of a research protocol for IRB review 
by all cooperating institutions participating in the research project. 
The CDC IRB will review and approve the protocol initially and on at 
least an annual basis until the research project is completed.
    e. Obtain an assurance of confidentiality, clearance from CDC's 
Office of Management and Budget (OMB), and other clearances as 
appropriate.
    f. Collaborate to produce technical reports or manuscripts for 
peer-reviewed publications as appropriate.

E. Content

Letter of Intent (LOI)

    A LOI is optional for this program. However, a non-binding LOI to 
apply is requested from potential applicants. The narrative should be 
no more than 2, single-spaced pages, printed on one side, with one inch 
margins, and unreduced font. Your letter should include the following 
information: announcement number, name of the principal investigator, 
and specifically which Parts the applicant plans to apply for.

Pre-application Conference Call

    A pre-application conference call is scheduled for June 20th at 
1:00 p.m. Eligible applicants are invited to participate in this 
conference call. The purpose of the conference call will be to 
communicate the logistics of the application process and to respond to 
any questions applicants may have regarding this announcement. 
Participation in this conference call is optional. A summary of the 
questions and answers will be made available for those unable to 
participate. Registration information for this conference call will be 
sent to all eligible applicants by June 15th.

Applications

    Use the information in the Program Requirements, Other 
Requirements, and Evaluation Criteria sections for Parts I-IV to 
develop the application content. Your application will be evaluated on 
the criteria listed, so it is important to follow them in laying out 
your program plan. The narrative for each Part should be no more than 
25 double-spaced pages, printed on one side, with one inch margins, and 
unreduced font. The original and each copy of the application must be 
submitted unstapled and unbound. Pages should be clearly numbered and a 
complete index to the application and any appendices included.
    Applicants may apply for support under one or more of the four 
Parts. Only one application should be submitted. For each Part include 
a separate and complete narrative, separate budget, and justification 
that can stand alone as an application for review purposes.
    Include funding for staff for Parts I, II, III, and IV to attend 
(1) a 1-day, post-award meeting in Atlanta; and (2) an additional 2-day 
meeting in a city to be determined later.
    The narrative should consist of, at a minimum, a Plan, Objectives, 
Methods, Evaluation and Budget.

F. Submission and Deadline

Letter of Intent (LOI)

    On or before June 8, 2001, submit the LOI to the Grants Management 
Specialist identified in the ``Where to Obtain Additional Information'' 
section of this announcement.

Application

    Submit the original and five copies of PHS-398 (OMB Number 0925-
0001) (adhere to the instructions on the Errata Instruction Sheet for 
PHS 398). Forms are available in the application kit and at the 
following Internet address:
http://www.cdc.gov/od/pgo/forminfo.htm.
    On or before July 1, 2001, submit the application to the Grants 
Management Specialist identified in the ``Where to Obtain Additional 
Information'' section of this announcement.

[[Page 29819]]

    Deadline: Applications shall be considered as meeting the deadline 
if they are either:
    1. Received on or before the deadline date; or
    2. Sent on or before the deadline date and received in time for 
submission to the independent review group. (Applicants must request a 
legibly dated U.S. Postal Service postmark or obtain a legibly dated 
receipt from a commercial carrier or U.S. Postal Service. Private 
metered postmarks shall not be acceptable as proof of timely mailing.)
    Late: Applications which do not meet the criteria in 1. or 2. above 
will be returned to the applicant.

G. Evaluation Criteria

    Each application will be evaluated individually against the 
following criteria by an independent review group appointed by CDC.

Budget (not scored)

    The extent to which the budget is reasonable, clearly justified, 
consistent with the demonstrated need and proposed activities, and 
likely to lead to program success.

Human Subjects (not scored)

    Does the application adequately address the requirements of Title 
45 CFR Part 46 for the protection of human subjects? (Not scored; 
however, an application can be disapproved if the research risks are 
sufficiently serious and protection against risks is so inadequate as 
to make the entire application unacceptable.)
    Specific evaluation criteria for each part are as follows:

Part I

1. Program Need (5 points)
    a. The extent to which the applicant demonstrates an effective 
understanding of the background of the problem (variable quality of 
patterns of care and validity of stage and treatment data in the 
registry), a need for the project, and a commitment to its execution. 
(3 points)
    b. The degree to which the applicant has met the CDC Policy 
requirements regarding the inclusion of women, ethnic, and racial 
groups in the proposed research. This includes:
    (1) The proposed plan for the inclusion of both sexes (not 
applicable for Breast or Prostate sites) and racial and ethnic minority 
populations for appropriate representation.
    (2) The proposed justification when representation is limited or 
absent.
    (3) A statement as to whether the design of the study is adequate 
to measure differences when warranted.
    (4) A statement as to whether the plans for recruitment and 
outreach for study participants include the process of establishing 
partnerships with community(ies) and recognition of mutual benefits. (2 
points)
2. Objectives (10 points)
    a. The extent to which the applicant demonstrates that the proposed 
program objectives are measurable, specific, time-phased, and related 
to the recipient activities, program purpose, and program need. (3 
points)
    b. The extent to which a description regarding the feasibility of 
implementing a North American/European study protocol such as the 
Concord study protocol and U.S. point of contact activities, including 
collecting and reporting data from medical abstract review and 
processing and reporting data to the Concord Analytic Data Center in 
Rome, Italy, and the extent to which feasibility is demonstrated by the 
description. (7 points)
3. Methods (40 points)
    a. The extent to which the applicant describes strengths and 
limitations for implementing a North American/European study protocol 
such as the Concord study, the U.S. patterns of care activities, and 
(optional) breast cancer screening linkage study. (10 points)
    b. The extent to which the applicant demonstrates sufficient 
knowledge, capacity and plans to implement and coordinate data 
collection, data reporting, and data linkage, given the strengths and 
limitations described. (20 points)
    c. The extent to which the applicant describes appropriate use of 
technology to apply to the collection, linkage and processing of the 
data. (5 points)
    d. The extent to which plans for collaborative data analysis and 
manuscript preparation are included. (5 points)
4. Evaluation (20 points)
    The extent to which the applicant describes adequate plans for 
providing on-going communication including feedback and quality control 
suggestions for improvement and implementation of study protocols.
5. Program Management and Staffing Plan (25 points)
    The extent to which proposed staffing, management and 
organizational structure, staff background and experience, job 
descriptions and resumes with qualifying experience of key personnel 
indicate an ability to carry out the project.

Part II

1. Program Need (15 points)
    a. The extent to which the applicant demonstrates an effective 
commitment and understanding to the project, as documented through 
letters of support, background and need for a standardized pathology 
report. (5 points)
    b. The extent to which a description regarding the impact of using 
standardized content in the collection and reporting of pathology data 
in general, and specifically for the targeted cancer sites, colon and 
rectum, is provided. (5 points)
    c. The extent to which a description of the need for standardized, 
electronic reporting of pathology data for the targeted cancers to 
cancer registries is provided. (5 points)
2. Plan of Operation (45 points)
    a. The extent to which a plan is provided to determine the 
strengths and limitations for implementation of the SNOMED-encoded CAP 
protocols for the target sites, for both clinical purposes and cancer 
surveillance purposes. (5 points)
    b. The extent to which the applicant proposes to apply clinical 
ANSI standards and others, such as HL7, SNOMED and Logical Identifiers, 
Names, and Codes (LOINC), to the implementation of the protocols and 
subsequent data reporting for surveillance purposes. (7 points)
    c. The extent to which the applicant provides sufficient knowledge, 
capacity and plans to work with clinical ANSI standards and others, 
such as HL7, SNOMED and LOINC. (7 points)
    d. The extent to which the applicant proposes methodologies for 
implementation of the protocols, which are standards-based, flexible, 
and portable for other protocols and data reporting environments. (6 
points)
    e. The extent to which the applicant addresses the electronic 
reporting challenges, needs, and strategies to implement the protocol. 
(6 points)
    f. The extent to which the applicant plans to follow through with 
the electronic reporting of the protocol. (5 points)
    g. The extent to which the applicant proposes to use technologies 
for the implementation of the protocol. (3 points)
    h. The extent to which proposed technologies are linked with 
existing capacities. (4 points)
    i. The degree to which the applicant has met the CDC Policy 
requirements

[[Page 29820]]

regarding the inclusion of women, ethnic, and racial groups in the 
proposed research. This includes:
    (1) The proposed plan for the inclusion of both sexes and racial 
and ethnic minority populations for appropriate representation.
    (2) The proposed justification when representation is limited or 
absent.
    (3) A statement as to whether the design of the study is adequate 
to measure differences when warranted.
    (4) A statement as to whether the plans for recruitment and 
outreach for study participants include the process of establishing 
partnerships with community(ies) and recognition of mutual benefits. (2 
points)
3. Evaluation (20 points)
    a. The extent to which the applicant describes plans providing 
feedback and quality control suggestions to the improvement and 
implementation of the protocol for the needs of pathologists and cancer 
registries. (10 points)
    b. The extent to which the applicant plans to analyze and document 
the impact of the protocol on the collection and reporting of timely, 
complete, accurate, and uniform pathology-related data. (10 points)
4. Project Management and Staffing Plan (20 points)
    a. The extent to which proposed staffing, management and 
organizational structure, staff background and experience, job 
descriptions and resumes with qualifying experience of key personnel 
indicate an ability to carry out the project. (10 points)
    b. The extent to which the applicant provides appropriate 
documentation regarding key partners (including pathologists and/or 
registry personnel) and their involvement in the project. (10 points)

Part III

1. Program Need (5 points)
    The extent to which the applicant demonstrates an effective 
understanding of the background of the problem (variable quality of 
patterns of care and validity of stage and treatment data in the 
registry), a need for the project, and a commitment to its execution.
2. Objectives (10 points)
    The extent to which the applicant demonstrates that the proposed 
program objectives are measurable, specific, time-phased, and related 
to the recipient activities, program purpose, and program need.
3. Methods (40 points)
    a. The extent to which the applicant demonstrates sufficient 
knowledge, capacity and plans to implement and coordinate data 
collection, data reporting activities, and data linkage, given the 
strengths and limitations described. (20 points)
    b. The extent to which the applicant describes appropriate use of 
technology to apply to the collection, linkage and processing of the 
data. (10 points)
    c. The extent to which plans for collaborative data analysis and 
manuscript preparation are included. (5 points)
    d. The degree to which the applicant has met the CDC Policy 
requirements regarding the inclusion of women, ethnic, and racial 
groups in the proposed research. This includes: (5 points)
    (1) The proposed plan for the inclusion of racial and ethnic 
minority populations for appropriate representation.
    (2) The proposed justification when representation is limited or 
absent.
    (3) A statement as to whether the design of the study is adequate 
to measure differences when warranted.
    (4) A statement as to whether the plans for recruitment and 
outreach for study participants include the process of establishing 
partnerships with community(ies) and recognition of mutual benefits.
4. Evaluation (20 points)
    The extent to which the applicant provides an evaluation plan that 
is appropriate for measuring progress toward achieving objectives and 
identifying contributing factors when objectives are not met.
5. Project Management and Staffing Plan (25 points)
    The extent to which proposed staffing, management and 
organizational structure, staff background and experience, job 
descriptions and resumes with qualifying experience of key personnel 
indicate an ability to carry out the project.

Part IV

1. Program Need (15 points)
    The extent to which the applicant demonstrates eligibility as 
required under this program announcement, describes existing strengths 
and limitations of the registry, and provides evidence of access to 
adequate numbers of oral and pharyngeal cancer cases by race and gender 
to support accomplishment of the project purpose.
2. Objectives (15 points)
    The extent to which the applicant demonstrates that the proposed 
program objectives are measurable, specific, time-phased, and related 
to the recipient activities, program purpose, and program need.
3. Methods (35 points)
    a. The extent to which the applicant adequately describes (23 
points)
    (1) The methods that will be used to accomplish the objectives of 
the project, including plans to sample an adequate number of cases for 
assessing completeness and data quality.
    (2) Proposed strategies and activities that are appropriate and 
feasible to achieve the project.
    b. The extent to which the timetable incorporates project 
activities and milestones and is specific, measurable, and realistic. 
(10 points)
    c. The degree to which the applicant has met the CDC Policy 
requirements regarding the inclusion of women, ethnic, and racial 
groups in the proposed research. This includes:
    (1) The proposed plan for the inclusion of both sexes and racial 
and ethnic minority populations for appropriate representation.
    (2) The proposed justification when representation is limited or 
absent.
    (3) A statement as to whether the design of the study is adequate 
to measure differences when warranted.
    (4) A statement as to whether the plans for recruitment and 
outreach for study participants include the process of establishing 
partnerships with community(ies) and recognition of mutual benefits. (2 
points)
4. Evaluation (15 points)
    The extent to which the applicant provides an evaluation plan that 
is appropriate for measuring accomplishment of project objectives and 
identifying contributing factors when objectives are not met.
5. Project Management and Staffing Plan (20 points)
    The extent to which proposed staffing, management and 
organizational structure, staff background and experience, job 
descriptions and resumes with qualifying experience of key personnel 
indicate ability to carry out the project.

H. Other Requirements

    Provide CDC with original plus two copies of
    1. an annual progress report, addressing progress toward achieving 
objectives detailed in the application,

[[Page 29821]]

due 90 days after the end of each budget period;
    2. a financial status report, no more than 90 days after the end of 
the budget period; and
    3. a final financial and performance report, no more than 90 days 
after the end of the project period.
    Send all reports to the Grants Management Specialist identified in 
the ``Where to Obtain Additional Information'' section of this 
announcement.
    The following additional requirements are applicable to this 
program. For a complete description of each, see Attachment I of the 
announcement.
AR-1  Human Subjects Requirements
AR-2  Requirements for Inclusion of Women and Racial and Ethnic 
Minorities in Research
AR-7  Executive Order 12372 Review
AR-8  Public Health System Reporting Requirements
AR-9  Paperwork Reduction Act Requirements
AR-10  Smoke-Free Workplace Requirements
AR-11 Healthy People 2010
AR-12 Lobbying Restrictions
AR-22 Research Integrity

I. Authority and Catalog of Federal Domestic Assistance Number

    This program is authorized under section 399H-399L of the Public 
Health Service Act, [42 U.S.C. sections 280e-280e-4; Public Law 102-
515], as amended. The Catalog of Federal Domestic Assistance number is 
93.283.

J. Where To Obtain Additional Information

    This and other CDC announcements can be found on the CDC home page 
Internet address--http://www.cdc.gov. Click on ``Funding'' then 
``Grants and Cooperative Agreements.''
    To obtain business management technical assistance, contact:
Jesse Robertson, Grants Management Specialist, Grants Management 
Branch, Procurement and Grants Office, Centers for Disease Control and 
Prevention, Announcement 01102, 2920 Brandywine Road, Room 3000, MS-
E18, Atlanta, GA 30341-4146, Telephone number: (770) 488-2747, Email 
address: <a href="/cdn-cgi/l/email-protection#b3d9c1dcd1d6c1c7c0dcddf3d0d7d09dd4dcc5"><span class="__cf_email__" data-cfemail="8ce6fee3eee9fef8ffe3e2ccefe8efa2ebe3fa">[email protected]</span></a>
    For program technical assistance, contact:

Part I

Hannah Weir, PhD, Cancer Surveillance Branch, Division of Cancer 
Prevention and Control, National Center for Chronic Disease Prevention 
and Health Promotion, Centers for Disease Control and Prevention, 4770 
Buford Hwy., NE, MS-K53, Atlanta, GA 30341-3717, Telephone number: 
(770) 488-3006, Email address: <a href="/cdn-cgi/l/email-protection#c4acb3a1adb684a7a0a7eaa3abb2"><span class="__cf_email__" data-cfemail="573f20323e251734333479303821">[email protected]</span></a>

Part II

Warren Williams, MPH, Cancer Surveillance Branch, Division of Cancer 
Prevention and Control, National Center for Chronic Disease Prevention 
and Health Promotion, Centers for Disease Control and Prevention, 4770 
Buford Hwy., NE, MS-K53, Atlanta, GA 30341-3717, Telephone number: 
(770) 488-3095, Email address: <a href="/cdn-cgi/l/email-protection#c4b3b3ada8a8ada5a9b7f584a7a0a7eaa3abb2"><span class="__cf_email__" data-cfemail="b9ceced0d5d5d0d8d4ca88f9daddda97ded6cf">[email protected]</span></a>

Part III

    Pamela Logan, MD, MPH, Cancer Surveillance Branch, Division of 
Cancer Prevention and Control, National Center for Chronic Disease 
Prevention and Health Promotion, Centers for Disease Control and 
Prevention, 4770 Buford Hwy., NE, MS-K53, Atlanta, GA 30341-3717, 
Telephone number: (770) 488-4292, Email address: <a href="/cdn-cgi/l/email-protection#b9c9d5d6ded8d7f9daddda97ded6cf"><span class="__cf_email__" data-cfemail="90e0fcfff7f1fed0f3f4f3bef7ffe6">[email protected]</span></a>

Part IV

Claudia Vousden, RN, MPH, Program Services Branch, Division of Oral 
Health, National Center for Chronic Disease Prevention and Health 
Promotion, Centers for Disease Control and Prevention, 4770 Buford 
Hwy., NE, MS-F10, Atlanta, GA 30341-3717, Telephone number: (770) 488-
6056, Email address: <a href="/cdn-cgi/l/email-protection#4526332a303621202b052621266b222a33"><span class="__cf_email__" data-cfemail="4023362f353324252e002324236e272f36">[email protected]</span></a>

    Dated: May 25, 2001.
Henry S. Cassell, III,
Acting Director, Procurement and Grants Office, Center for Disease 
Control and Prevention (CDC).
[FR Doc. 01-13738 Filed 5-31-01; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>